Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID

Chapuis-Biron, Constance; Kirchgesner, Julien; Pariente, Benjamin; Bouhnik, Yoram; Amiot, Aurélien; Viennot, S; Serrero, Mélanie; Fuméry, Mathurin; Allez, Matthieu; Siproudhis, Laurent; Buisson, Anthony; Pineton de Chambrun, Guillaume; Abitbol, Véred; Nancey, Stéphane; Caillo, Ludovic; Plastaras, Laurianne; Savoye, Guillaume; Chanteloup, Elise; Simon, Marion; Dib, Nina; Rajca, Sylvie; Amil, Morgane; Parmentier, Anne-Laure; Peyrin‐Biroulet, Laurent; Vuitton, Lucine; Biolap Study Group, Getaid

doi:10.14309/ajg.0000000000000810

Public

Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID

Published in The American Journal of Gastroenterology • Aug 19, 2020

Authors:

Constance Chapuis-Biron

Julien Kirchgesner

Benjamin Pariente

Abstract

INTRODUCTION: New therapeutic options for patients with Crohn's disease (CD) with perianal lesions failing anti-tumor necrosis factor (TNF) agents are needed. We aimed to assess the effectiveness of ustekinumab in perianal CD (pCD) and predictors of clinical success in a real-life multicenter cohort...

Subject

Medicine

Ustekinumab

Crohn's disease

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!